European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
Search
Why we may be more like our pets than we think
The bond between owners and their pets goes beyond physical resemblance as we are increasingly facing similar health problems.
It Takes 2
It Takes 2 people – a patient and a HCP, and 2 tests – a blood and a urine test–to help detect CKD. Early testing can drive earlier diagnosis and treatment.
world rabies day 2019
world rabies day 2019
Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
The chronic nature of generalized pustular psoriasis
Understanding the impact of the physical and psychological symptoms of this chronic disease.
Phase II results cognitive impairment schizophrenia
Presented at ECNP Congress, Phase II trial results demonstrated improvement in cognition with BI 425809 in schizophrenia patients
Boehringer Ingelheim Social Engagements
Boehringer Ingelheim Social Engagements Contributes to company commitment to impact 50 million people in vulnerable communities by 2030 through supporting social entrepreneurs and innovative solutions
Retinal Diseases
Retinal Diseases
More Potential Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Nurjanahs Story
Nurjanah went from a sporty young woman to someone who no longer had the energy to do simple, everyday tasks. She was diagnosed with scleroderma.
2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
The Unwearable Collection™ Evolution
Get ready for the next stage of The Unwearable Collection™
Partnership to further develop pet market in China
Boehringer Ingelheim invests in partnership to further develop the pet market in China, acquires a stake in New Ruipeng Group
New African Swine Fever Manual published
Boehringer Ingelheim joined forces with the leading veterinarians to fight African swine fever. The new African Swine Fever Knowledge Handbook published.
Boehringer receives SBTi validation for CO2 reduction targets
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
World Water Day: Good Health Hinges on Good Water
Clean, safe and accessible water is the most basic prerequisite for life and health
Health for all: How can we contribute to inclusive access?
What drives us to improve the health of humans and animals worldwide
MASH
MASH
environmental sustainability commitments
On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
Sharing knowledge from our medical device development
Why do we share some of our work beyond Boehringer for free?
sustainably fighting rabies info hub
Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
Innovating for our business
We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.
Boehringer Ingelheim attends WVPAC 2019
Boehringer Ingelheim attends and showcases its leading vaccines and services at 21st World Veterinary Poultry Association Congress
Respimat re-usable wins Pharmapack Eco-Design Award
The Respimat® re-usable inhaler device has won the 2020 Pharmapack Eco-Design Award. An enhanced version of the Respimat® soft mist inhaler, Respimat® re-usable has a lower environmental impact and is easy for patients to use.